Print

CEVEC Pharma Licenses its Proprietary Human Cell Lines to Paragon Bioservices, Inc.  
8/2/2012 10:28:13 AM

Cologne, Germany, August 2, 2012 / B3C newswire / - CEVEC Pharmaceuticals, the developer of a novel, market-leading human protein expression system derived from amniocytes, and Paragon Bioservices, Inc., a leading contract research and GMP manufacturing organization with a focus on the development and manufacturing of biopharmaceuticals, announced a joint collaboration earlier today-whereby Paragon Bioservices would license and use CEVEC's know-how and patents (on CAP and CAP-T cell expression system) to develop stable cell lines and perform process development for the contract manufacturing of recombinant proteins and antibodies.

"We are very pleased to be working with Paragon Bioservices," said Wolfgang Kintzel, CEVEC's CEO. "Since they provide preclinical research and development services and protein production for many of the large pharmaceutical companies, we believe that our collaboration will inevitably benefit the research community at-large." Paragon's CEO, Marco Chacón, PhD, agrees, "Even though our upstream developmental team has many years of experience in cell biology and bioprocess development, this is a highly competitive business. Everyone needs an edge to meet the outsourcing challenges of our clients. This valuable tool from CEVEC will assist us in offering clients a fully optimized human expression system that will express proteins with superior yields and in a shorter time frame than traditional methods. We look forward to a long relationship with CEVEC."

About CEVEC Pharmaceuticals GmbH

CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC's novel proprietary and patent-protected human CAP® and CAP-T T expression systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing out its human cell-based expression platform as well as its own biobetter candidates through partnerships with renowned pharmaceutical and biotech companies.

About Paragon Bioservices, Inc.

Paragon is a Contract Research & GMP Manufacturing Organization (CMO) delivering research, development and manufacturing services. Paragon's focus is biopharmaceuticals, including recombinant proteins, viral vectors, vaccines, VLPs, bacteriophage and stem cells. Our clients include pharmaceutical companies, biotechnology companies and federal agencies.

Contacts:

Wolfgang Kintzel

CEO

CEVEC Pharmaceuticals GmbH

Gottfried-Hagen Straße 62

D-51105 Köln, Germany

fon +49 (0) 221-46 02 08 - 00

fax +49 (0) 221-46 02 08 - 01

info@cevec.com

Marco A. Chacón, Ph.D.

President & CEO

Paragon Bioservices, Inc.

Baltimore, MD 21201

ph (410)975-4050 or (410) 975-4052

machacon@paragonbioservices.com or

sales-support@paragonbioservices.com